Krystal Biotech (NASDAQ:KRYS) Shares Gap Down – What’s Next?

Krystal Biotech, Inc. (NASDAQ:KRYS) gapped down before the market opened on Wednesday . The stock had previously closed at $156.69, but opened at $149.25. Krystal Biotech shares last traded at $164.70, with a volume of 78,905 shares changing hands.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on KRYS shares. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a report on Thursday. Chardan Capital boosted their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Citigroup boosted their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech has an average rating of “Buy” and an average price target of $210.00.

Krystal Biotech Stock Performance

The firm’s 50-day moving average is $157.37 and its two-hundred day moving average is $175.23. The stock has a market cap of $5.40 billion, a P/E ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech’s revenue was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.30 EPS. As a group, research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new stake in shares of Krystal Biotech during the 3rd quarter valued at $40,000. Values First Advisors Inc. bought a new stake in shares of Krystal Biotech during the 3rd quarter valued at $53,000. GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech in the 4th quarter valued at $95,000. Huntington National Bank increased its position in shares of Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after buying an additional 283 shares in the last quarter. Finally, Blue Trust Inc. increased its position in shares of Krystal Biotech by 242.4% in the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after buying an additional 412 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).